Demodex injai: A new species of hair follicle mite (Acari : Demodecidae) from the domestic dog (Canidae)

Department of Ecology and Evolutionary Biology, University of Connecticut, Storrs, Connecticut, United States
Journal of Medical Entomology (Impact Factor: 1.82). 04/2003; 40(2):146-9. DOI: 10.1603/0022-2585-40.2.146
Source: PubMed

ABSTRACT Demondex injai sp. nov. is described from the hair follicles of a domestic dog in Columbus, OH in October 1996. The mites occupy follicles from the orifice down to and into the sebaceous glands. The individual host may harbor both this new species and D. canis. A comparison of these two species is provided for identification purposes.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In bee families untreated with acaricide substances during the active season population trends of infestation with Varroa destructor mites by determining indicators, daily natural mortality, level of infestation of adult bees and level of infestation of the brood, was monitored. In results interpretation was established that, in climatic conditions of western Romania, V. destructor mite populations in bee families under active season may reach, in the fall at the end of the active beekeeping season, damaging levels in the absence of specific treatment.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This laboratory study compared the efficacy of Bravecto™ (fluralaner), formulated as a chewable tablet, with the efficacy of Advocate® (imidacloprid/moxidectin), formulated for topical administration, against naturally acquired generalized demodicosis in dogs. Sixteen dogs, all diagnosed with generalized demodectic mange, were randomly allocated to two equal groups. Bravecto™ chewable tablets were administered once orally at a minimum dose of 25 mg fluralaner/kg body weight to one group of dogs, while the second group was treated topically on three occasions at 28-day intervals with Advocate® at a minimum dose of 10 mg imidacloprid/kg body weight and 2.5 mg moxidectin/kg body weight. Mites were counted in skin scrapings and demodectic lesions were evaluated on each dog before treatment and at 28-day intervals thereafter over a 12 week study period. Deep skin scrapings (~4 cm(2)) were made from the same five sites on each dog at each subsequent examination. After single oral administration of Bravecto™ chewable tablets, mite numbers in skin scrapings were reduced by 99.8% on Day 28 and by 100% on Days 56 and 84. Mite numbers in the dogs treated topically on three occasions at 28-day intervals with Advocate® were reduced by 98.0% on Day 28, by 96.5% on Day 56 and by 94.7% on Day 84. Statistically significantly (P ≤ 0.05) fewer mites were found on Days 56 and 84 on the Bravecto™ treated dogs compared to Advocate® treated dogs. A marked decrease was observed in the occurrence of erythematous patches, crusts, casts and scales in the dogs treated with Bravecto™ and in the occurrence of erythematous patches in the dogs treated with Advocate®. With the exception of one dog in each treated group, all dogs exhibited hair regrowth ≥ 90% at the end of the study in comparison with their hair-coat at study start. Single oral administration of Bravecto™ chewable tablets is highly effective against generalized demodicosis, with no mites detectable at 56 and 84 days following treatment. In comparison, Advocate®, administered three times at 28-day intervals, is also highly effective against generalized demodicosis, but most dogs still harboured mites at all assessment time points. Both treatments resulted in a marked reduction of skin lesions and increase of hair re-growth 12 weeks after the initial treatment.
    Parasites & Vectors 03/2015; 8(1):187. DOI:10.1186/s13071-015-0775-8 · 3.25 Impact Factor
  • 03/2007; 12(2). DOI:10.1111/j.2044-3862.2007.tb00131.x